Physician profile
William B Holmes
NPI 1528001815
$12,333.77
in general payments reported to CMS, 2019-2025
60 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $1,446 · 2021: $2,156 · 2022: $1,848 · 2023: $1,485 · 2024: $1,546 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,773.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,616.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,540.35 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $869.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $731.99 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $673.17 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.49 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $479.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $477.31 | 2019-2022 | |
| Lilly USA, LLC | $432.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $388.08 | 2019-2023 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $330.06 | 2021-2024 | Nexletol, Nexlizet |
| Incyte Corporation | $273.40 | 2023-2025 | Opzelura |
| Astellas Pharma US INC | $224.27 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.62 | 2019-2021 | |
| Dynavax Technologies Corporation | $156.20 | 2022-2025 | Heplisav-B |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.